Practice
Featured experience
Chime $993.6 million IPO
The shares are listed on the Nasdaq Global Select Market
Cipher Mining 300 MW, $5.5 billion lease agreement with Amazon Web Services
We advised Cipher Mining on the transaction
Diameter Capital Partners $4.5 billion fundraise for its third dislocation fund
We advised Diameter on the transaction
Banco Santander $12.2 billion acquisition of Webster Bank
We are advising Banco Santander on the transaction
BBVA €1.1 billion asset-backed notes offering
Davis Polk advised Banco Bilbao Vizcaya Argentaria, S.A. on the offering of asset-backed notes with an aggregate face value…
Shockwave Medical $89.4 million stock offering
Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 1,955,000 shares of common stock for an…
Aviation Capital Group cash tender offer
Davis Polk advised the dealer manager in connection with a cash tender offer by Aviation Capital Group LLC to purchase…
Shockwave Medical $89.4 million stock offering
Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 1,955,000 shares of common stock for an…
Seagate HDD Cayman $500 million exchange offers
Davis Polk advised the lead dealer managers in connection with the Rule 144A/Regulation S exchange offers by…
Trebia Acquisition $517.5 million IPO
Davis Polk advised the underwriters in connection with the initial public offering of 51,750,000 units of Trebia…
Ocado Group £1 billion offerings of ordinary shares and convertible bonds
Davis Polk advised Ocado Group plc as to U.S. law in connection with its placing of 33,163,265 new ordinary shares with…
Royalty Pharma $2.5 billion IPO
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering…
Royalty Pharma $2.5 billion IPO
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering…
Royalty Pharma $2.5 billion IPO
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering…